Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
| ▸ | KLK1 | P06870 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6320145 | 0.90 | TACR1 (0.39) | S1PR1MMP1MMP3TACR1KLKB1 | |
| SCHEMBL6324203 | 0.89 | GHSR (0.35) | CTSCCYP3A4S1PR1ADAM17CTSS | |
| SCHEMBL6317859 | 0.88 | GHSR (0.43) | CTSCCYP3A4ADAM17MMP1LMNA | |
| SCHEMBL6318940 | 0.85 | MMP12 (0.38) | S1PR1MMP1MMP3MAPK14TACR1 | |
| SCHEMBL6319672 | 0.85 | GHSR (0.44) | CTSCCYP3A4TACR1KLKB1KLK1 | |
| SCHEMBL6326078 | 0.84 | S1PR1 (0.39) | S1PR1MMP1MMP3TACR1KLKB1 | |
| SCHEMBL6318098 | 0.83 | MMP2 (0.36) | CTSCCTSSTACR1KLKB1KLK1 | |
| SCHEMBL6325560 | 0.82 | CTSS (0.35) | S1PR1CTSSMMP1MMP3 | |
| SCHEMBL8210349 | 0.81 | CTSC (0.35) | CTSCCYP3A4ADAM17MMP1MMP3 | |
| SCHEMBL6320315 | 0.80 | TRPM8 (0.35) | CTSCCYP3A4ADAM17CTSSKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030055261-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-03-20 | — | — | US | claimed |
| US-20030040483-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-02-27 | — | — | US | claimed |
| EP-0869974-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1998-10-14 | — | — | EP | claimed |
| US-6939880-B2 | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 2005-09-06 | — | — | US | disclosed |
| US-6555570-B2 | Growth hormone secretagogous with improved bioavailability | NOVO NORDISK A/S (DE) | 2003-04-29 | — | — | US | disclosed |
| US-20030055261-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-03-20 | — | — | US | disclosed |
| US-20030040483-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-02-27 | — | — | US | disclosed |
| US-6127391-A | A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY | NOVO NORDISK A/S (DK) | 2000-10-03 | — | — | US | disclosed |
| US-5977178-A | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 1999-11-02 | — | — | US | disclosed |
| EP-0869974-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997023508-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055261-A1 | Compounds with growth hormone releasing properties | GHRHR, GHSR, IGFBP1 | CTSC 242/4885CYP3A4 3623/4885S1PR1 717/4885 |
| US-20030040483-A1 | Compounds with growth hormone releasing properties | GHRHR, GHSR, GRPR | CTSC 234/4885CYP3A4 3566/4885S1PR1 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.